GlassScriptPhysician profile
Jack W Horng
NPI 1922093376
$1,503.38
in general payments reported to CMS, 2019-2025
25 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $67.47 · 2022: $85.27 · 2023: $138 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $208.78 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Pulmonx Corporation | $184.00 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Insmed, INC. | $158.89 | 2019-2025 | Arikayce |
| Biofire Diagnostics, LLC | $138.26 | 2019 | |
| Philips North America LLC | $102.94 | 2019-2020 | |
| Inspire Medical Systems, INC. | $97.05 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $85.27 | 2022 | |
| Mylan Specialty L.P. | $81.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $36.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.75 | 2019 | |
| Genzyme Corporation | $31.88 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.71 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $28.64 | 2025 | Lumryz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $27.67 | 2025 | Ohtuvayre |
| Electromed, INC. | $24.95 | 2019 | |
| Harmony Biosciences LLC | $24.93 | 2025 | |
| Novo Nordisk INC | $22.00 | 2025 | Wegovy |
| Amgen INC. | $21.92 | 2025 | Tezspire |
| Circassia INC. | $17.13 | 2020 | |
| Amarin Pharma, INC. | $16.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.27 | 2023 | Eliquis |
| Pfizer INC. | $14.49 | 2019 | |
| Genentech USA, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Horng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.